On July 30, Corcept Therapeutics rose 15.98% in regular trading, trading at $116.38/share, with turnover of $96.01 million.

The surge was driven by the company's Q2 earnings report released after market close the prior session. Corcept posted EPS of $0.36, dramatically exceeding the analyst consensus estimate of $0.02 and representing a 24.14% year-over-year increase. Revenue reached $256.1 million, up from $194.4 million a year earlier, beating the $221.1 million estimate by approximately 16%.

The company simultaneously raised full-year revenue guidance to $1.1 billion to $1.2 billion, well above the prior forecast of $950 million to $1.05 billion and the FactSet consensus of $999.5 million. The strong results were primarily driven by the commercial momentum of core product Korlym and newly approved drug Lifyorli. Additionally, the company resubmitted its NDA for Relacorilant for Cushing's syndrome treatment in June, and Canaccord Genuity raised its price target from $135 to $150, further boosting investor confidence.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)